Arcus Biosciences, Inc. Earnings Per Share, Basic and Diluted
Arcus Biosciences, Inc. (RCUS) reported Earnings Per Share, Basic and Diluted of -$0.93 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-03
- Arcus Biosciences, Inc. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.93.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.96.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.09.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$1.08.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for fiscal 2020 was -$2.24.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for fiscal 2019 was -$1.93.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for fiscal 2018 was -$1.43.
- Arcus Biosciences, Inc. earnings per share, basic and diluted for fiscal 2017 was -$29.03.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.93 10-Q · filed 2022-08-03 | -$1.88 10-Q · filed 2022-08-03 | ||
| 2022-03-31 | -$0.96 10-Q · filed 2022-05-09 | |||
| 2021-06-30 | -$1.09 10-Q · filed 2022-08-03 | -$2.17 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | -$1.08 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$2.24 10-K · filed 2021-02-25 | |||
| 2020-06-30 | -$0.93 10-Q · filed 2021-08-05 | -$1.57 10-Q · filed 2021-08-05 | -$1.96 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$2.47 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2020-03-31 | -$0.63 10-Q · filed 2021-05-05 | -$1.00 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.51 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$2.15 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2019-12-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$0.89 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.53 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.93 10-K · filed 2021-02-25 |
| 2019-09-30 | -$0.51 10-Q · filed 2019-11-05 | -$1.15 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.56 10-Q · filed 2019-11-05 | -$1.84 derived: net income ÷ weighted average shares · filed 2021-02-25 |
| 2019-06-30 | -$0.64 10-Q · filed 2020-08-06 | -$1.05 10-Q · filed 2020-08-06 | -$1.33 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.59 derived: net income ÷ weighted average shares · filed 2021-02-25 |
| 2019-03-31 | -$0.41 10-Q · filed 2020-05-05 | -$0.69 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$0.94 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.26 derived: net income ÷ weighted average shares · filed 2021-02-25 |
| 2018-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$0.54 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$0.86 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$1.43 10-K · filed 2021-02-25 |
| 2018-09-30 | -$0.25 10-Q · filed 2019-11-05 | -$0.57 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$1.16 10-Q · filed 2019-11-05 | -$2.08 derived: net income ÷ weighted average shares · filed 2020-03-05 |
| 2018-06-30 | -$0.32 10-Q · filed 2019-08-06 | -$1.01 10-Q · filed 2019-08-06 | -$2.20 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$4.47 derived: net income ÷ weighted average shares · filed 2020-03-05 |
| 2018-03-31 | -$1.37 10-Q · filed 2019-05-02 | -$4.47 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$10.84 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$15.34 derived: net income ÷ weighted average shares · filed 2020-03-05 |
| 2017-12-31 | -$5.98 derived: net income ÷ weighted average shares · filed 2019-03-05 | -$17.48 derived: net income ÷ weighted average shares · filed 2019-03-05 | -$23.53 derived: net income ÷ weighted average shares · filed 2019-03-05 | -$29.03 10-K · filed 2019-03-05 |
| 2017-09-30 | -$11.86 10-Q · filed 2018-11-08 | -$17.94 derived: net income ÷ weighted average shares · filed 2019-03-05 | -$23.47 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$5.64 10-Q · filed 2018-08-06 | -$10.66 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | -$4.96 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$20.80 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |